Wednesday, October 14, 2026

Corn Futures Slides By 12% In The Last 21 Sessions

Corn Futures Slides By 12% In The Last 21 Sessions

(VIANEWS) - Corn (ZC) has been up by 12.48% for the last 21 sessions. At 02:52 EST on Thursday, 11 July, Corn (ZC) is $408.50.

Volume

Today's last reported volume for Corn is 44951, 66.7% below its average volume of 135015.76.

Volatility

Corn's last week, last month's, and last quarter's current intraday variation average was a negative 0.79%, a negative 0.33%, and a positive 2.49%, respectively.

Corn's highest amplitude of average volatility was 0.79% (last week), 0.69% (last month), and 2.49% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Corn's commodity is considered to be overbought (>=80).

News about

  • Crude oil eases on Tuesday despite extended decline in API barrel counts. According to FXStreet on Tuesday, 9 July, "West Texas Intermediate (WTI) US Crude Oil extended a near term decline on Tuesday, falling to $81.00 per barrel as American Crude Oil markets continue to struggle to find consistent bullish momentum.", "Tropical Storm Beryl, which was downgraded from a category 1 hurricane, also failed to disrupt US Crude Oil markets as much as barrel traders had initially feared, kicking the legs out from underneath a near-term bullish push and keeping WTI bids pinned on the low side."
  • According to FXStreet on Thursday, 11 July, "This is seen underpinning Crude Oil prices amid a modest US Dollar (USD) weakness.", "The outlook keeps the USD bulls on the defensive and seems to benefit the USD-denominated commodities, including Crude Oil prices."

More news about Corn (ZC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com